Garetosmab, activin A inhibitor antibody for muscle-preservation combination regimens in obesity Recent Highlights: In June 2026, the company announced it would present new clinical data from the Phase 2 COURAGE trial that examines the effects of trevogrumab (anti-GDF8) on lean mass in people with obesity treated with semaglutide
Disclaimer: PlatinumLionPeptides.com products are for research use only and are not intended for human or animal consumption
To be eligible for a Zepbound prescription near you, candidates must have a BMI of 30 or higher, or a BMI of 27 or higher with weight-related health conditions like high blood pressure, heart disease, type 2 diabetes, high cholesterol, or sleep apnea
Clinical Trials: Semaglutide has undergone extensive clinical trials to evaluate its impact on cardiovascular outcomes
Broad-spectrum 14 panel drug test kits for comprehensive screening